This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Subject Data Story Boards

From HL7Wiki
Revision as of 18:42, 31 October 2008 by Daveih (talk | contribs) (New page: == Links == Stage 1B Project page == Class 1 – Sponsor Planned Data == Data collected in accordance with the plan.  The Study Design message conveys (among ot...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Links

Stage 1B Project page

Class 1 – Sponsor Planned Data

Data collected in accordance with the plan.  The Study Design message conveys (among other things) the plan for data collection, the Study Participation message includes information on the subjects in the study, and thus those two messages imply an expected set of data to be collected. The subject data message needs to be able to convey that data.

1.

Study A1234 is complete and Acme Pharmaceuticals now wants to send to the FDA all the observations recorded for each subject during the study as part of their study report submission. Acme uses the CDISC-HL7 subject data message to provide all the recorded observations, as well as all the derived parameters resulting from those observations, as defined by the CDISC SDTM and ADaM standards. The message contains all important relationships, such as the relationship between an observed and planned assessment (or lack thereof), and the relationship between unplanned assessments and other observations (i.e. physical exam finding of jaundice led to a bilirubin measurement). Those observations that were previously reported in a spontaneous adverse event report are not re-submitted, but rather updated and referenced.

2.

FDA runs some form of check to assess if all planned activities were performed. This requires access to the plan held within the Study Design message and needs to allow for all paths to be evaluated at a high level of detail definition (sufficient to allow for a machine to perform the check)

3.

Planned data being captured but study is high risk and therefore FDA requested that data be provided at regular intervals while the trial is running